FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology. Bispecific antibody that specifically binds to human HER2 or Javanese macaque and HER3 is described, comprising: a VHH heavy chain variable domain that specifically binds to HER3, wherein the VHH heavy chain variable domain comprises amino acid sequences, at least 75 % homologous to the sequences of SEQ ID NO: 1–3, and an antibody or an antigen-binding domain thereof that specifically bind to human HER2 or Javanese macaque.
EFFECT: invention also relates to DNA encoding the said antibody corresponding to an expression vector and a production method, as well as to a method of treatment using the said bispecific antibody.
31 cl, 36 dwg, 27 ex, 7 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION CONTAINING ANTIBODY BINDING TO DOMAIN II OF HER2, AND ITS ACIDIC VERSIONS | 2009 |
|
RU2543664C2 |
| COMPOSITION OF HER2 ANTIBODIES | 2005 |
|
RU2361880C2 |
| BISPECIFIC ASYMMETRIC HETERODIMERS COMPRISING ANTI-CD3 CONSTRUCTS | 2013 |
|
RU2650868C2 |
| ANTI-PD-1 ANTIBODIES, METHOD FOR THEIR PRODUCTION, AND METHOD OF APPLICATION | 2016 |
|
RU2656181C1 |
| THERAPY OF MALIGNANT TUMOR, RESISTANT TO PLATINUM-BASED MEDICATIONS | 2005 |
|
RU2403065C2 |
| INTRODUCTION OF FIXED DOSES OF HER-ANTIBODIES | 2005 |
|
RU2438705C2 |
| ANTI-LRP6 ANTIBODIES | 2011 |
|
RU2587625C2 |
| MEANS OF IDENTIFICATION OF TUMOURS, ACQUISITIVE TO TREATMENT BY ANTIBODIES AGAINST ErbB2 | 2003 |
|
RU2338751C2 |
| ALLOSTERIC ANTIBODIES AGAINST HUMAN HER3 NON COMPETITIVE FOR NEUREGULIN AND USE THEREOF | 2013 |
|
RU2704228C2 |
| MONOCLONAL PD-L1 ANTIBODY | 2017 |
|
RU2665790C1 |
